Vitamins China E-News 202308
In Aug., vitamin prices, while being generally stable at relatively low levels, differed in trends.
The raw material supply situation's bolstering effects on VB3 price weakened, which dampened the market traders' faith in the price. Therefore, VB3 price in Aug. showed a retracement from the high level.
The downstream customers were cautious in making price inquires for VB5; VB5 sales transactions were slack overall; VB5 price dipped MoM, thus showing a wilting trend.
Supply of VB6 was rather tight. The number of VB6 sales transactions kept growing. Market price of VB6 in Aug. continued the rising trend.
VE price in Aug. delivered a marginal increase and remained stable. End-users in the downstream generally purchased VE to satisfy their rigid demand. During transaction price negotiation, purchase quantities were taken into consideration.
NMPA stated that some drugs of Beijing Langdi Pharmaceutical Co., Ltd. (Langdi Pharma), totalling 32 batches, had been found non-conforming in terms of vitamin D3 content. The shares of Langdi Pharma's products in the Chinese market remain high. The incident has aroused the attention of consumers.
As of 16 Aug., four listed enterprises that engage in vitamins issued their reports of H1 2023 results, including: Bluestar Adisseo Co., Ltd., Zhejiang Garden Biopharmaceutical Co., Ltd. (former name: Zhejiang Garden Biochemical High-tech Co., Ltd.), Brother Enterprises Holding Co., Ltd. and Tianjin Zhongrui Pharmaceutical Co., Ltd.
News about several projects has been reported, including: North China Pharmaceutical Co., Ltd. Beida Branch Factory's 'vitamin K2 and coenzyme Q10 flexible production line project'; Ningxia Tianxin Pharmaceutical Co., Ltd.'s fine chemicals project; Inner Mongolia Kingdomway Pharmaceutical Co., Ltd.'s '10,000 t/a calcium pantothenate construction project'; Jilin Beisha Pharmaceutical Co., Ltd.'s '2,3,5-Trimethylhydroquinone (TMHQ) technical renovation project'; Jilin GSH Bio-technology Co., Ltd.'s 'project of ?-Nicotinamide mononucleotide (NMN) production via enzyme method and its industrialisation'; Jilin Tianchi Biotechnology Co., Ltd.'s '80,000 t/a feed additives project'.
The USD/CNY exchange rate in this Report is USD1.00=CNY7.1283, which was sourced from the People's Bank of China on 1 Aug., 2023. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
The raw material supply situation's bolstering effects on VB3 price weakened, which dampened the market traders' faith in the price. Therefore, VB3 price in Aug. showed a retracement from the high level.
The downstream customers were cautious in making price inquires for VB5; VB5 sales transactions were slack overall; VB5 price dipped MoM, thus showing a wilting trend.
Supply of VB6 was rather tight. The number of VB6 sales transactions kept growing. Market price of VB6 in Aug. continued the rising trend.
VE price in Aug. delivered a marginal increase and remained stable. End-users in the downstream generally purchased VE to satisfy their rigid demand. During transaction price negotiation, purchase quantities were taken into consideration.
NMPA stated that some drugs of Beijing Langdi Pharmaceutical Co., Ltd. (Langdi Pharma), totalling 32 batches, had been found non-conforming in terms of vitamin D3 content. The shares of Langdi Pharma's products in the Chinese market remain high. The incident has aroused the attention of consumers.
As of 16 Aug., four listed enterprises that engage in vitamins issued their reports of H1 2023 results, including: Bluestar Adisseo Co., Ltd., Zhejiang Garden Biopharmaceutical Co., Ltd. (former name: Zhejiang Garden Biochemical High-tech Co., Ltd.), Brother Enterprises Holding Co., Ltd. and Tianjin Zhongrui Pharmaceutical Co., Ltd.
News about several projects has been reported, including: North China Pharmaceutical Co., Ltd. Beida Branch Factory's 'vitamin K2 and coenzyme Q10 flexible production line project'; Ningxia Tianxin Pharmaceutical Co., Ltd.'s fine chemicals project; Inner Mongolia Kingdomway Pharmaceutical Co., Ltd.'s '10,000 t/a calcium pantothenate construction project'; Jilin Beisha Pharmaceutical Co., Ltd.'s '2,3,5-Trimethylhydroquinone (TMHQ) technical renovation project'; Jilin GSH Bio-technology Co., Ltd.'s 'project of ?-Nicotinamide mononucleotide (NMN) production via enzyme method and its industrialisation'; Jilin Tianchi Biotechnology Co., Ltd.'s '80,000 t/a feed additives project'.
The USD/CNY exchange rate in this Report is USD1.00=CNY7.1283, which was sourced from the People's Bank of China on 1 Aug., 2023. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
Headline
Editor's Note
Governmental Direction
NMPA issues circular on non-conforming VD3 content in 32 batches of Langdi Pharma's drugs
Market Dynamics
Four listed vitamin producers disclose H1 2023 results
Company Developments
Two projects to be financed by Kingdomway's convertible bonds issuance undergoing EIA publication
EP facilities in Phase I of NCPC Beida Branch Factory's VK2 and CoQ10 project accepted
Approval granted to EI report of Ningxia Tianxin's fine chemicals project
EI report of Kaiping Genuine Biochemical's biochemical raw material project to obtain approval
Beisha Pharma to self-produce TMHQ for VE production
Eastroc Beverage delivers YoY growth in H1 2023 results
Import and Export Analysis
Imports and exports of selected vitamins in China, June 2023
China's vitamin exports in H1 2023 dips 7.25% YoY
Price Update
Ex-works prices of selected vitamins in China, Aug. 2023
Vitamin prices in Aug. differ in trends
News in Brief
Kindos Pharma's generic version of Leucovorin Calcium for Injection approved by US FDA
Hwatson Biochem to halt production and conduct overhaul in vitamin base
Kingdomway and its subsidiary obtain new invention patent certificate
EI report of Jilin GSH's NMN production project approved
Approval granted to EI report of Tianchi Biotech's 80,000 t/a feed additives project
NHC denies authorisation of chemically-synthesised VK2 as new food additive
EI report of Tianyin Biotech's sodium ascorbyl phosphate and tanning agent project accepted
Cargill's animal nutrition factory in Fujian Province comes on stream
Construction of Hubei Magic Health's functional health product project under way
dsm-firmenich reports YoY drop in sales for H1 2023
Editor's Note
Governmental Direction
NMPA issues circular on non-conforming VD3 content in 32 batches of Langdi Pharma's drugs
Market Dynamics
Four listed vitamin producers disclose H1 2023 results
Company Developments
Two projects to be financed by Kingdomway's convertible bonds issuance undergoing EIA publication
EP facilities in Phase I of NCPC Beida Branch Factory's VK2 and CoQ10 project accepted
Approval granted to EI report of Ningxia Tianxin's fine chemicals project
EI report of Kaiping Genuine Biochemical's biochemical raw material project to obtain approval
Beisha Pharma to self-produce TMHQ for VE production
Eastroc Beverage delivers YoY growth in H1 2023 results
Import and Export Analysis
Imports and exports of selected vitamins in China, June 2023
China's vitamin exports in H1 2023 dips 7.25% YoY
Price Update
Ex-works prices of selected vitamins in China, Aug. 2023
Vitamin prices in Aug. differ in trends
News in Brief
Kindos Pharma's generic version of Leucovorin Calcium for Injection approved by US FDA
Hwatson Biochem to halt production and conduct overhaul in vitamin base
Kingdomway and its subsidiary obtain new invention patent certificate
EI report of Jilin GSH's NMN production project approved
Approval granted to EI report of Tianchi Biotech's 80,000 t/a feed additives project
NHC denies authorisation of chemically-synthesised VK2 as new food additive
EI report of Tianyin Biotech's sodium ascorbyl phosphate and tanning agent project accepted
Cargill's animal nutrition factory in Fujian Province comes on stream
Construction of Hubei Magic Health's functional health product project under way
dsm-firmenich reports YoY drop in sales for H1 2023
